Latest Breaking News On - Nct02446093 - Page 1 : comparemela.com

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

Candel therapeutics incCandel therapeuticsPeter takFast track designation to aglatimagene besadenovec plus valacyclovirPatients with pancreatic ductal adenocarcinomaPaul peter tak